[Reactivation and aging of acetylcholinesterase in human brain inhibited by phoxim and phoxim oxon in vitro].
OBJECTIVE
Inhibition of acetylcholinesterase (AChE) in human brain caused by phoxim or phoxim oxon, their reactivation with oxime and aging of phosphorylated AChE were studied and compared in vitro.


METHODS
Micro-colorispectrophotometric assay was used to determine the activity of AChE.


RESULTS
The pI(50) of inhibition of AChE in human brain by phoxim and phoxim oxon were 5.39 and 5.77, respectively, whereas the pI(90) were 4.60 and 5.00, respectively. The reactivation rate of 0.1 mmol/L of pralidoxime (2-PAM), obidoxime (LüH(6)), trimedoxime (TMB-4) and pyramidoxime (HI-6) for phoxim-inhibited AChE in human brain was 65%, 97%, 91% and 56%, respectively, and their reactivation rate for phoxim oxon-inhibited AChE in human brain was 97%, 87%, 99% and 89%, respectively. The optimal reactivator for phoxim and phoxim oxon-inhibited AChEs was LüH(6) and TMB-4, respectively. The half aging time of phoxim and phoxim oxon inhibited phosphorylated AChEs were 39 and 28 hours, respectively, and the 99% aging time were 256 and 186 hours, respectively.


CONCLUSIONS
LüH(6) or TMB-4 should be used at the earlier as possible after poisoning with phoxim and phoxim oxon, and the reactivator should be consecutively used for more than seven days, even after their acute symptoms have been well controlled.
Li
Jintong
J
Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China.
Zhang
Yu
Y
Du
Xianlin
X
Sun
Manji
M
D000110:Acetylcholinesterase / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000201:enzymology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002801:Cholinesterase Reactivators / Q000494:pharmacology*; D004795:Enzyme Stability; D006801:Humans; D066298:In Vitro Techniques; D009768:Obidoxime Chloride / Q000494:pharmacology; D009946:Organothiophosphorus Compounds / Q000494:pharmacology*; D010091:Oximes / Q000494:pharmacology; D010261:Paraoxon / Q000494:pharmacology*; D011220:Pralidoxime Compounds / Q000494:pharmacology; D013997:Time Factors; D014289:Trimedoxime / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D002801:Cholinesterase Reactivators; D009946:Organothiophosphorus Compounds; D010091:Oximes; D011220:Pralidoxime Compounds; D009768:Obidoxime Chloride; D014289:Trimedoxime; C003135:phoxim; D000110:Acetylcholinesterase; C028797:pralidoxime; D010261:Paraoxon